Posts by Sandra Ansanay-Alex
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
SOPHiA GENETICS is a leader in AI-driven precision medicine based in Lausanne (Switzerland). The company announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions. SOPHiA DDM™ Digital Twins uses each patient’s unique…
Read More19th Innovation Day at HUG: Meet the Winners!
At their 19th Innovation Day, the Geneva University Hospitals (HUG) highlighted 16 innovative projects from the hospital and academic sectors, grouped into three categories: Proof of Concept, Prototype, and Launch-Ready Product. Top 3 Awarded Projects: 🥇 Flow Twin: A 3D modeling platform of brain vessels for training, planning personalized endovascular procedures, and testing new…
Read MoreADC Therapeutics Announces $60 Million Private Placement
ADC Therapeutics SA, a Vaud-based commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity (“PIPE”) financing. In the PIPE, ADC Therapeutics…
Read MoreHealth.Tech Global Summit
The Health.Tech Global Summit is taking place from 3 to 5 March 2026 in Basel The health.tech Summit brings together global leaders, innovators, and visionaries at the forefront of healthcare transformation. Through expert guidance and collaboration, our event delivers groundbreaking insights, meaningful connections, and a future-focused vision for the industry. More than 5,000 participants…
Read MoreRelief Therapeutics merges with NeuroX to form MindMaze Therapeutics
The new entity, valued at CHF 1.1 billion, is positioned as a leader in neurotechnology. The transaction is expected to close in December 2025. RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, and NeuroX Group SA (NeuroX), a privately held company focused on digital…
Read MorePrêt ? Partez, Pitch ! – The Finale
The finale of GENILEM’s contest, Prêt ? Partez, Pitch !, is taking place on 3 December 2025 at the Musée Olympique in Lausanne. PRÊT ? PARTEZ, PITCH ! was launched by GENILEM in 2020 to support and promote innovative entrepreneurship in our region! Through this competition, we highlight up-and-coming projects and give them the…
Read MoreLICR, CHUV and UNIL extend their collaboration and renew their partnership
The Canton of Vaud, the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL) and the Ludwig Institute for Cancer Research (LICR) have signed a new agreement. This agreement extends the presence of the Ludwig branch in Lausanne and strengthens their collaboration. This partnership has already attracted world-renowned scientists in the field of cancer. It…
Read MoreUCB Farchim Invests Over CHF 100 Million and Creates 80 New Jobs in Bulle
UCB Farchim, the Swiss subsidiary of Belgian biopharmaceutical group UCB, has announced a major new phase of development for its Bulle (Fribourg) site, with more than CHF 100 million in new investments and the creation of 80 additional jobs by 2030. Since opening in 1996, UCB has invested nearly CHF 700 million in its…
Read MoreHemostOD Secures CHF 4.3M Seed Extension
HemostOD, a Swiss Health Valley company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, announces the successful closing of a CHF 4.3 million Seed-extension financing. The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors. Proceeds from this financing…
Read MoreAI-Powered Precision Oncology: NAIPO Launches in Switzerland
A new national initiative, NAIPO (National AI Initiative for Precision Oncology), is set to transform cancer care in Switzerland by leveraging artificial intelligence (AI) to enable truly personalized treatments. Led by the EPFL AI Center and ETH AI Center, NAIPO will run over four years and bring together a large, interdisciplinary team from Swiss…
Read More